Haleon Acquires 12% Stake in Chinese Joint Venture for Full Ownership

On July 8, Haleon, a global leader in consumer health, announced the completion of its acquisition of the remaining 12% stake in its non-prescription drug joint venture, Tianjin Sino-American Schering-Plough Pharmaceutical Co., Ltd. This acquisition marks the full ownership of the company by Haleon, which previously held 45% of the shares. Tianjin Sino-American Schering-Plough is now a wholly-owned subsidiary of Haleon.

This strategic move by Haleon is aimed at strengthening its position in the non-prescription drug market in China. The acquisition allows Haleon to consolidate its operations and enhance its market presence, leveraging the established distribution network and brand recognition of Tianjin Sino-American Schering-Plough. By fully integrating the operations, Haleon can streamline its supply chain, reduce operational costs, and improve efficiency. This acquisition is part of Haleon's broader strategy to expand its footprint in the rapidly growing non-prescription drug market in China, which is driven by increasing consumer awareness of health and wellness.

Tianjin Sino-American Schering-Plough focuses on categories such as pain management, respiratory health, skin health, and digestive health. The company boasts a portfolio of well-known brands, including Fenbid, New Kantek, Biduobang, Futaolin, and Fushuliang. These brands are expected to complement Haleon's existing product offerings and further solidify its market leadership in China.

Haleon's acquisition of Tianjin Sino-American Schering-Plough is a significant step in its efforts to strengthen its non-prescription drug portfolio. The company has been actively pursuing growth opportunities in the non-prescription drug market, which is expected to continue to grow due to the aging population and increasing demand for over-the-counter medications. By acquiring Tianjin Sino-American Schering-Plough, Haleon can leverage its extensive product portfolio and strong brand recognition to capture a larger share of the market.

The acquisition also allows Haleon to tap into the growing demand for non-prescription drugs in China, which is driven by the increasing prevalence of chronic diseases and the rising awareness of preventive healthcare. By acquiring Tianjin Sino-American Schering-Plough, Haleon can position itself to capitalize on this growth opportunity and strengthen its market position in China.

In summary, Haleon's acquisition of Tianjin Sino-American Schering-Plough is a strategic move aimed at strengthening its position in the non-prescription drug market in China. The acquisition allows Haleon to consolidate its operations, enhance its market presence, and tap into the growing demand for non-prescription drugs in China. This acquisition is part of Haleon's broader strategy to expand its footprint in the rapidly growing non-prescription drug market, which is driven by increasing consumer awareness of health and wellness.